Review
Zafirlukast
No authors listed
In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
.
- PMID:31643251
- Bookshelf ID: NBK547915
Item in Clipboard
Review
Zafirlukast
No authors listed.
Free Books & Documents Display options
Format
Display options
Format
Excerpt
Zafirlukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma. Zafirlukast has been linked to rare, but occasionally severe cases of acute liver injury.
Sections
Similar articles
- Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma.Kelloway JS.Kelloway JS.Ann Pharmacother. 1997 Sep;31(9):1012-21. doi: 10.1177/106002809703100912.Ann Pharmacother. 1997.PMID:9296243Review.
- Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.Adkins JC, Brogden RN.Adkins JC, et al.Drugs. 1998 Jan;55(1):121-44. doi: 10.2165/00003495-199855010-00008.Drugs. 1998.PMID:9463793Review.
- Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast.Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ.Reinus JF, et al.Ann Intern Med. 2000 Dec 19;133(12):964-8. doi: 10.7326/0003-4819-133-12-200012190-00011.Ann Intern Med. 2000.PMID:11119397
- Summary of clinical trials with zafirlukast.Calhoun WJ.Calhoun WJ.Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):S238-46.Am J Respir Crit Care Med. 1998.PMID:9620946
- Asthma outcome changes associated with use of the leukotriene-receptor antagonist zafirlukast.Klingman D, Bielory L, Wang Y, Silverman S, Bell CF, Joy KA, Dever MT, Jones DA.Klingman D, et al.Manag Care Interface. 2001 Feb;14(2):62-6.Manag Care Interface. 2001.PMID:11228819
References
- Zimmerman HJ. Respiratory supportive drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, p. 717.(Expert review of hepatotoxicity published in 1999; mentions that theophylline has been incriminated in hepatic injury rarely; no mention of montelukast, zafirlukast or zileuton).
- Lewis JH. Nonsteroidal anti-inflammatory drugs and leukotriene receptor antagonists. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013. pp. 389-90.(Expert review of liver injury caused by leukotriene receptor antagonists mentions that there were no reports of clinically apparent liver injury during premarketing studies of zafirlukast, but that more than 100 reports of clinically apparent injury appeared thereafter, at least 14 resulting in liver failure).
- Barnes PJ. Pulmonary pharmacology. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 727-30.(Textbook of pharmacology and therapeutics).
- Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206. (Review article on leukotriene pathway in asthma and rhinitis and efficacy and safety of montelukast, zafirlukast and zileuton; mentions that abnormal ALT elevations can occur). - PubMed
- Gozalo Reques F, Estrada Rodriguez JL. Tolerability of leukotriene modifiers in asthma: a review of clinical experience. Biodrugs 1999; 11: 385-94. (Review of safety of leukotriene antagonists without new information). - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources